Wen-Xiu Xu1, Jian Zhang1, Yu-Ting Hua2, Su-Jin Yang1, Dan-Dan Wang1, Jin-Hai Tang1. 1. Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. 2. Department of Gastroenterology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, China.
Abstract
BACKGROUND: Lipocalin 2 (LCN2), an innate immune protein, plays a pivotal role in promoting sterile inflammation by regulating immune responses. However, the role of LCN2 in diverse cancers remains poorly defined. This research aimed to investigate the correlation between LCN2 expression and immunity and visualize its prognostic landscape in pan-cancer. METHODS: Raw data in regard to LCN2 expression in cancer patients were acquired from TCGA and GTEx databases. Besides, we investigated the genomic alterations, expression pattern, and survival analysis of LCN2 in pan-cancer across numerous databases, including cBioPortal and GEPIA database. The correlation between LCN2 expression and tumor immune infiltration was explored via TIMER, and we utilized CIBERSORT and ESTIMATE computational methods to assess the proportion of tumor-infiltrating immune cells (TIICs) and the amount of stromal and immune components from TCGA database. Protein-Protein Interaction analysis was performed in GeneMANIA database, and gene functional enrichment was performed by Gene Set Enrichment Analysis (GSEA). RESULTS: On balance, tumor tissue had a higher LCN2 expression level compared with that in normal tissue. Elevated expression of LCN2 was related to poor clinical regimen with OS and RFS. There were significant positive correlations between LCN2 expression and TIICs, including CD8+ T cells, CD4+ T cells, B cells, neutrophils, macrophages, and dendritic cells. Moreover, markers of TIICs exhibited different LCN2-related immune infiltration patterns. GSEA analysis showed that the expression of LCN2 was related to retinol metabolism, drug metabolism cytochrome P450 and metabolism of xenobiotics by cytochrome P450. CONCLUSIONS: These findings suggested that LCN2 might serve as a biomarker for immune infiltration and poor prognosis in cancers, shedding new light on therapeutics of cancers.
BACKGROUND: Lipocalin 2 (LCN2), an innate immune protein, plays a pivotal role in promoting sterile inflammation by regulating immune responses. However, the role of LCN2 in diverse cancers remains poorly defined. This research aimed to investigate the correlation between LCN2 expression and immunity and visualize its prognostic landscape in pan-cancer. METHODS: Raw data in regard to LCN2 expression in cancer patients were acquired from TCGA and GTEx databases. Besides, we investigated the genomic alterations, expression pattern, and survival analysis of LCN2 in pan-cancer across numerous databases, including cBioPortal and GEPIA database. The correlation between LCN2 expression and tumor immune infiltration was explored via TIMER, and we utilized CIBERSORT and ESTIMATE computational methods to assess the proportion of tumor-infiltrating immune cells (TIICs) and the amount of stromal and immune components from TCGA database. Protein-Protein Interaction analysis was performed in GeneMANIA database, and gene functional enrichment was performed by Gene Set Enrichment Analysis (GSEA). RESULTS: On balance, tumor tissue had a higher LCN2 expression level compared with that in normal tissue. Elevated expression of LCN2 was related to poor clinical regimen with OS and RFS. There were significant positive correlations between LCN2 expression and TIICs, including CD8+ T cells, CD4+ T cells, B cells, neutrophils, macrophages, and dendritic cells. Moreover, markers of TIICs exhibited different LCN2-related immune infiltration patterns. GSEA analysis showed that the expression of LCN2 was related to retinol metabolism, drug metabolism cytochrome P450 and metabolism of xenobiotics by cytochrome P450. CONCLUSIONS: These findings suggested that LCN2 might serve as a biomarker for immune infiltration and poor prognosis in cancers, shedding new light on therapeutics of cancers.
Authors: Sobeyda B Gomez-Chou; Agnieszka Katarzyna Swidnicka-Siergiejko; Niharika Badi; Myrriah Chavez-Tomar; Gregory B Lesinski; Tanios Bekaii-Saab; Matthew R Farren; Thomas A Mace; Carl Schmidt; Yan Liu; Defeng Deng; Rosa F Hwang; Liran Zhou; Todd Moore; Deyali Chatterjee; Huamin Wang; Xiaohong Leng; Ralph B Arlinghaus; Craig D Logsdon; Zobeida Cruz-Monserrate Journal: Cancer Res Date: 2017-03-01 Impact factor: 12.701
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: Brian G Drew; Habib Hamidi; Zhenqi Zhou; Claudio J Villanueva; Susan A Krum; Anna C Calkin; Brian W Parks; Vicent Ribas; Nareg Y Kalajian; Jennifer Phun; Pedram Daraei; Heather R Christofk; Sylvia C Hewitt; Kenneth S Korach; Peter Tontonoz; Aldons J Lusis; Dennis J Slamon; Sara A Hurvitz; Andrea L Hevener Journal: J Biol Chem Date: 2014-12-02 Impact factor: 5.157
Authors: Patrícia Domingues; María González-Tablas; Álvaro Otero; Daniel Pascual; David Miranda; Laura Ruiz; Pablo Sousa; Juana Ciudad; Jesús María Gonçalves; María Celeste Lopes; Alberto Orfao; María Dolores Tabernero Journal: Brain Behav Immun Date: 2015-07-26 Impact factor: 7.217
Authors: Edoardo Missiaglia; Ekaterini Blaveri; Benoit Terris; Yao-He Wang; Eithne Costello; John P Neoptolemos; Tatjana Crnogorac-Jurcevic; Nicholas R Lemoine Journal: Int J Cancer Date: 2004-10-20 Impact factor: 7.396
Authors: Yuen Ping Chong; Evelyn Priya Peter; Feon Jia Ming Lee; Chu Mun Chan; Shereen Chai; Lorni Poh Chou Ling; Eng Lai Tan; Sook Han Ng; Atsushi Masamune; Siti Aisyah Abd Ghafar; Norsharina Ismail; Ket Li Ho Journal: Sci Rep Date: 2022-07-19 Impact factor: 4.996
Authors: Yiguan Qian; Yang Li; Ke Chen; Ning Liu; Xi Hong; Di Wu; Zheng Xu; Liuhua Zhou; Luwei Xu; Ruipeng Jia; Yu-Zheng Ge Journal: J Inflamm Res Date: 2022-02-16
Authors: Roderic Espín; Alexandra Baiges; Eline Blommaert; Carmen Herranz; Antonio Roman; Berta Saez; Julio Ancochea; Claudia Valenzuela; Piedad Ussetti; Rosalía Laporta; José A Rodríguez-Portal; Coline H M van Moorsel; Joanne J van der Vis; Marian J R Quanjel; Anna Villar-Piqué; Daniela Diaz-Lucena; Franc Llorens; Álvaro Casanova; María Molina-Molina; Mireya Plass; Francesca Mateo; Joel Moss; Miquel Angel Pujana Journal: Mol Cancer Res Date: 2021-07-26 Impact factor: 6.333